Teva Pharmaceuticals has announced the completion of its acquisition of Barr Pharmaceuticals, for $7.46 billion, plus the assumption of roughly $1.5 billion in debt. Barr's generic business in the US will extend Teva's product portfolio, while adding a substantial women's healthcare business, among other things, said Shlomo Yanai, Teva president and CEO, in a statement.
A US district court in California has dismissed a lawsuit against Amgen that claimed the company had promoted two anemia drugs – Epogen and Aranesp – off-label. The court said government regulators, and not private companies or individuals, had the right to bring such an action. The lawsuit was filed as a class action suit, involving claims made by seven health benefit plan providers.